Humacyte Receives U.S. Patent Covering Symvess and Other Bioengineered Tissues
Humacyte says a new U.S. patent covers Symvess and other bioengineered tissues.
Related stories
Integer Holdings Reports Q3 Revenue of $449.7M
Integer Holdings reported Q3 revenue of $449.7M, compared with a FactSet estimate of $456.9M.
M impact | EQUITY | Oct 29, 2026, 12:17 PM UTC
Establishment Labs Posts Q3 Net Loss of $0.35 per Share
The company reported a Q3 net loss of $0.35 per share, versus FactSet's estimate of a $0.26 loss.
M impact | EQUITY | Oct 29, 2026, 12:11 PM UTC
H2O America launches 6.5 million-unit equity offering
H2O America commenced an underwritten public offering of 6.5 million equity units.
L impact | EQUITY | Oct 29, 2026, 12:06 PM UTC
Federal Signal reports Q3 revenue of $655.5 million
Q3 revenue was $655.5 million, versus a FactSet estimate of $661.6 million.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC
Fluent to Report Third-Quarter 2026 Results on November 12
Fluent says it will announce its third-quarter 2026 financial results and host an earnings conference call on November 12, 2026.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC
Alnylam Reports Q3 Revenue of $1.46B
Alnylam reported Q3 revenue of $1.46 billion, versus a FactSet estimate of $1.43 billion.
M impact | EQUITY | Oct 29, 2026, 12:05 PM UTC